Drug Therapy and Interactions in Pediatric Oncology
Drug Therapy and Interactions in Pediatric Oncology
A Pocket Guide
de Menezes, Fabiana Gatti; Penteado Schmidt, Carolina Witchmichen
Springer International Publishing AG
11/2016
212
Mole
Inglês
9783319388717
15 a 20 dias
2892
2. The Main Diseases In Pediatric Oncohematology
2.1. Hodgkin Lymphoma
2.2. Chronic Myeloid Leukemia (CML)
2.3. Acute Myeloid Leukemia (AML)
2.4. Acute Lymphoblastic Leukemia (ALL)
2.5. Osteosarcoma
2.6. Central Nervous System Tumors.-
3. The Main Protocols In Pediatric Oncohematology
3.1. Hodgkin Lymphoma
3.2. Chronic Myeloid Leukemia (CML)
3.3. Hematologic Control with Hydroxyurea
3.4. Acute Myeloid Leukemia (AML)
3.5. Acute Myeloid Leukemia - Berlin-Frankfurt-Muenster Treatment (BFM2004) - adapted from HEMORIO
3.6. Acute Myeloid Leukemia - Berlin-Frankfurt-Muenster Treatment (BFM95)
3.7. Brain Tumors
3.8. High Dose Protocol - HD-CAV (Neuroblastoma)
3.9. COPE/Baby Brain I
3.10. 8 in 1 Chemotherapy
3.11. CAV-P/VP (Neuroblastoma)
3.12. Wilms Tumor
3.13. AVD
3.14. AV (Wilms Tumor Stage IV and Favorable Histology)
3.15. Advanced Burkkit Lymphoma and ALL L3
3.16. Burkkit Lymphoma Protocol LMB89
3.17. Retinoblastoma
3.18. Non-Hodgkin Lymphoma
3.19. CODOX-M
3.20. Osteosarcoma
3.21. HD MTX
3.22. ICE
3.23. Hepatoblastoma.-
4. Background On Drug Interactions
4.1. General Concepts
4.2. Pharmacokinetic Interactions
4.3. Pharmacodynamic Interactions
4.4. Beneficial Drug Interactions of Clinical Protocols
4.5. Methotrexate with Leocovorin
4.6. Doxorubicin with Dexrazoxane
4.7. Mesna with Ifosfamide or with Cyclophosphamide
4.8. Methotrexate with Sodium Bicarbonate
4.9. Drug-drug Interactions
4.10. Pharmacokinetic Drug Interactions with CYP450
4.11. Pharmacokinetic Drug Interactions with CYP450: Anticonvulsant
4.12. Pharmacokinetic Drug Interactions Involving Binding Proteins and Plasmatic Proteins Affinity
4.13. ?1- Acid Glycoprotein
4.14. Albumin
4.15. Pharmacokinetic Drug Interactions Involving Transport Proteins
4.16. P Glycoprotein
4.17. ATP Binding Cassettes
4.18. Drug Interactions Involving Prodrugs
4.19. Drug Interactions between Methotrexate and Nonsteroidal Anti-inflammatory Drugs
4.20. 6-Mercaptopurin and Allopurinol
4.21. Antineoplasics and Antiemetics
4.22. Aprepitant
4.23. Dexamethasone with Antineoplasics
4.24. Antacids with Antineoplasics
4.25. Antimicrobial Drugs with Antineoplasics
4.26. Macrolides Antimicrobial
4.27. Aminoglicosydes Antimicrobial
4.28. Tuberculosis Antimicrobial Drugs
4.29. Ceftriaxhone and Platinum Composers
4.30. Penicilamic Antibiotical Drug and Antineoplasics
4.31. Sulfamethoxazole withTrimethoprim and Methotrexate
4.32. Antineoplasics and Antifungics
4.33. Amphotericin B
4.34. Azolic Antifungics
4.35. Anticonvulsant and Antineoplasics.-
5. Food - Drug Interactions.-
6. Body Surface.-
7. Carboplatin Dosage Calculation.-
8. Creatinine Clearance Estimate
2. The Main Diseases In Pediatric Oncohematology
2.1. Hodgkin Lymphoma
2.2. Chronic Myeloid Leukemia (CML)
2.3. Acute Myeloid Leukemia (AML)
2.4. Acute Lymphoblastic Leukemia (ALL)
2.5. Osteosarcoma
2.6. Central Nervous System Tumors.-
3. The Main Protocols In Pediatric Oncohematology
3.1. Hodgkin Lymphoma
3.2. Chronic Myeloid Leukemia (CML)
3.3. Hematologic Control with Hydroxyurea
3.4. Acute Myeloid Leukemia (AML)
3.5. Acute Myeloid Leukemia - Berlin-Frankfurt-Muenster Treatment (BFM2004) - adapted from HEMORIO
3.6. Acute Myeloid Leukemia - Berlin-Frankfurt-Muenster Treatment (BFM95)
3.7. Brain Tumors
3.8. High Dose Protocol - HD-CAV (Neuroblastoma)
3.9. COPE/Baby Brain I
3.10. 8 in 1 Chemotherapy
3.11. CAV-P/VP (Neuroblastoma)
3.12. Wilms Tumor
3.13. AVD
3.14. AV (Wilms Tumor Stage IV and Favorable Histology)
3.15. Advanced Burkkit Lymphoma and ALL L3
3.16. Burkkit Lymphoma Protocol LMB89
3.17. Retinoblastoma
3.18. Non-Hodgkin Lymphoma
3.19. CODOX-M
3.20. Osteosarcoma
3.21. HD MTX
3.22. ICE
3.23. Hepatoblastoma.-
4. Background On Drug Interactions
4.1. General Concepts
4.2. Pharmacokinetic Interactions
4.3. Pharmacodynamic Interactions
4.4. Beneficial Drug Interactions of Clinical Protocols
4.5. Methotrexate with Leocovorin
4.6. Doxorubicin with Dexrazoxane
4.7. Mesna with Ifosfamide or with Cyclophosphamide
4.8. Methotrexate with Sodium Bicarbonate
4.9. Drug-drug Interactions
4.10. Pharmacokinetic Drug Interactions with CYP450
4.11. Pharmacokinetic Drug Interactions with CYP450: Anticonvulsant
4.12. Pharmacokinetic Drug Interactions Involving Binding Proteins and Plasmatic Proteins Affinity
4.13. ?1- Acid Glycoprotein
4.14. Albumin
4.15. Pharmacokinetic Drug Interactions Involving Transport Proteins
4.16. P Glycoprotein
4.17. ATP Binding Cassettes
4.18. Drug Interactions Involving Prodrugs
4.19. Drug Interactions between Methotrexate and Nonsteroidal Anti-inflammatory Drugs
4.20. 6-Mercaptopurin and Allopurinol
4.21. Antineoplasics and Antiemetics
4.22. Aprepitant
4.23. Dexamethasone with Antineoplasics
4.24. Antacids with Antineoplasics
4.25. Antimicrobial Drugs with Antineoplasics
4.26. Macrolides Antimicrobial
4.27. Aminoglicosydes Antimicrobial
4.28. Tuberculosis Antimicrobial Drugs
4.29. Ceftriaxhone and Platinum Composers
4.30. Penicilamic Antibiotical Drug and Antineoplasics
4.31. Sulfamethoxazole withTrimethoprim and Methotrexate
4.32. Antineoplasics and Antifungics
4.33. Amphotericin B
4.34. Azolic Antifungics
4.35. Anticonvulsant and Antineoplasics.-
5. Food - Drug Interactions.-
6. Body Surface.-
7. Carboplatin Dosage Calculation.-
8. Creatinine Clearance Estimate